Icure Pharmaceutical Incorporation (175250) — Cash Flow-to-Debt Ratio
Icure Pharmaceutical Incorporation (175250) has a Cash Flow-to-Debt Ratio of -0.05x as of March 2025, meaning its operating cash flow of ₩-3.28 Billion could theoretically repay 0% of its total liabilities (₩64.30 Billion) in one year. See 175250 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Icure Pharmaceutical Incorporation Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Icure Pharmaceutical Incorporation across 10 annual periods. Also explore net asset momentum of Icure Pharmaceutical Incorporation to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Icure Pharmaceutical Incorporation (2015–2024)
Year-by-year debt coverage analysis for Icure Pharmaceutical Incorporation. For market capitalisation and broader financial context, see Icure Pharmaceutical Incorporation stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.23x | ₩-17.05 Billion | ₩72.62 Billion | ▼ -85.1% |
| 2023 | -0.13x | ₩-13.52 Billion | ₩106.54 Billion | ▼ -51.2% |
| 2022 | -0.08x | ₩-11.28 Billion | ₩134.45 Billion | ▲ +61.7% |
| 2021 | -0.22x | ₩-26.23 Billion | ₩119.69 Billion | ▼ -46.6% |
| 2020 | -0.15x | ₩-12.40 Billion | ₩82.99 Billion | ▼ -197.4% |
| 2019 | -0.05x | ₩-5.94 Billion | ₩118.27 Billion | ▲ +75.0% |
| 2018 | -0.20x | ₩-7.30 Billion | ₩36.31 Billion | ▼ -754.6% |
| 2017 | 0.03x | ₩1.12 Billion | ₩36.43 Billion | ▲ +109.2% |
| 2016 | -0.33x | ₩-4.88 Billion | ₩14.58 Billion | ▼ -3209.8% |
| 2015 | -0.01x | ₩-204.05 Million | ₩20.19 Billion | — |